Natural clotting 'switch' may one day reduce reliance on blood thinners to prevent heart attacks and strokes
Researchers have identified a biological mechanism involving S1P and thrombomodulin that prevents blood clots without increasing bleeding risks. This discovery could lead to new therapies for heart attacks and strokes that serve as safer alternatives to traditional blood thinners.
Why it matters
This represents a significant potential advancement in cardiovascular medicine, offering a way to treat life-threatening conditions with fewer side effects.
by Anne Wansing, Heinrich-Heine University Duesseldorf
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source S1P inhibits platelet adhesion and thrombus formation in an endothelium- and TM-dependent manner. Mechanistically, activation of S1PR1 and PI3K mediates TM up-regulation. Credit: Science Advances (2026). DOI: 10.1126/sciadv.aea9826 Cardiovascular conditions such as strokes or heart attacks are among the most common causes of death in Germany. Today, treatment and prevention are primarily based on so-called platelet aggregation inhibitors and anticoagulants—types of medication commonly referred to as blood thinners. They inhibit or prevent blood coagulation, which in turn prevents the formation of blood clots and life-threatening medical emergencies such as strokes or heart attacks. However, by intervening directly in the hemostasis process, they increase the risk of dangerous bleeding.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in